

Understanding Your Positive TP53 Genetic Test Result

INFORMATION FOR PATIENTS WITH A PATHOGENIC OR LIKELY PATHOGENIC VARIANT

3 Things To Know

1	Result	Your testing shows that you have a pathogenic or likely pathogenic (P/LP) variant in the TP53 gene.
2	Reason for <i>TP53</i> P/LP variant	 A <i>TP53</i> P/LP variant may already be in a person's body at birth (germline), or may have occurred at some point during a person's lifetime (somatic). People with a germline P/LP <i>TP53</i> variant have Li Fraumeni syndrome People with a somatic P/LP <i>TP53</i> variant do NOT have Li Fraumeni syndrome
3	What this means for you	 It is important to discuss your result in detail with your healthcare provider. Your report will indicate whether your <i>TP53</i> P/LP variant may have occurred during your lifetime (somatic) or if your result is consistent with a diagnosis of Li Fraumeni syndrome. If your report has a COMMENT about the possibility of somatic origin, see "Pathogenic or Likely Pathogenic Variants of Unknown Origin in the <i>TP53</i> Gene" OR If your report states you have a pathogenic or likely pathogenic <i>TP53</i> variant with a diagnosis of Li Fraumeni syndrome" table on page 2

Pathogenic or Likely Pathogenic Variants of Unknown Origin in the *TP53* Gene Your test report includes a COMMENT about the possibility of somatic origin


Result	 Sometimes <i>TP53</i> P/LP variants occur naturally in a person's blood later in life. These types of variants can be observed even in healthy people, especially when they are over 65 years of age. Somatic <i>TP53</i> P/LP variants can also be seen in blood as a result of chemotherapy or radiation treatments. If your <i>TP53</i> P/LP variant is somatic, you do not have the same cancer risks associated with Li Fraumeni syndrome. It is important to discuss your specific management with your healthcare provider. It is not always possible to distinguish definitively between germline and somatic variants. It is important to discuss next steps with your healthcare provider and decide on a plan that works for you.
Other Medical Concerns	Somatic <i>TP53</i> P/LP variants are often detected in healthy people. However, some people with <i>TP53</i> P/LP variants in blood may be at an increased risk for heart disease or blood cancers. It is important to discuss your management and screening options with your healthcare provider.
Family	Testing your siblings, parents, and/or children can help determine if your <i>TP53</i> P/LP variant is germline or somatic. If it is somatic, then neither you nor your family are at increased risk for the types of cancers that are seen more often in people with Li Fraumeni syndrome.

Li Fraumeni Syndrome Your test report states that the result is consistent with a diagnosis of Li Fraumeni syndrome (LFS), which is caused by germline pathogenic or likely pathogenic variants in the <i>TP53</i> gene			
Li-Fraumeni syndrome	People with germline <i>TP53</i> P/LP variants have classic Li Fraumeni syndrome (LFS) or attenuated LFS. The attenuated form of LFS means that the risk of cancer may not be as high as in classic LFS.		
Cancer Risk	People with LFS due to germline <i>TP53</i> P/LP variants have an increased chance to develop adrenocortical carcinoma (ACC) [†] , female ^{**} breast cancer, brain tumors, choroid plexus carcinoma [†] , leukemia, medulloblastoma [†] , osteosarcoma, rhabdomyosarcoma [†] , soft tissue sarcoma, and potentially other types of cancer. The lifetime risk for cancer may be as high as 90% ^{††} for females ^{**} or 70% for males ^{**} . Cancer risks can vary widely, even within the same family.		
Risk Management	Risk management decisions are very personal. There are options to detect cancer early or lower the risk to develop cancer. It is important to discuss these options with your healthcare provider and decide on a plan that works for you.		
Family	Up to 20% of the time, a person is born with a <i>TP53</i> variant that was not inherited from either parent. Testing family members for the P/LP <i>TP53</i> variant found in you could help to determine who in your family may or may not be at increased risk. It is recommended that you share this information with your family members so they can learn more and discuss with their healthcare providers.		

These cancers are often diagnosed in childhood (<15 years).


†† Cumulative risk by age 60 years.

Cancer Risks Associated with Classic LFS



Germline *TP53* Variants in the Family[^]

There is up to a 50/50 random chance to pass on a germline P/LP TP53 variant to each of your children.



People with somatic *TP53* variants cannot pass them on to their children.

	Colon cancer risk estimates are 20% or higher.
*	Refers to sex assigned at birth



Please discuss this information with your healthcare provider. The cancer genetics field is continuously evolving, so updates related to your *TP53* result, medical recommendations, and/or potential treatments may be available over time. This information is not meant to replace a discussion with a healthcare provider, and should not be considered or interpreted as medical advice.

Clinician Management Resource for TP53

This overview of clinical management guidelines is based on this patient's positive test result for a pathogenic or likely pathogenic variant in the *TP53* gene. Unless otherwise stated, medical management guidelines used here are limited to those issued by the National Comprehensive Cancer Network® (NCCN®)¹ in the U.S. Please consult the referenced guideline for complete details and further information. Clinical correlation with the patient's past medical history, treatments, surgeries and family history may lead to changes in clinical management decisions; therefore, other management recommendations may be considered. Genetic testing results and medical society guidelines help inform medical management decisions but do not constitute formal recommendations. Discussions of medical management decisions and individualized treatment plans should be made in consultation between each patient and his or her healthcare provider, and may change over time.

NOTE:

- If the patient's report has a COMMENT about the possibility of acquired (somatic) origin, refer to the "Pathogenic or Likely Pathogenic Variants of Unknown Origin in the TP53 Gene" table below for management guidelines. See the NCCN Guidelines pages LIFR-A 1 through 3 for a more detailed discussion of causes and management of atypical TP53 findings.
- If the patient's report states that the pathogenic or likely pathogenic *TP53* variant is consistent with a diagnosis of Li Fraumeni syndrome, refer to the "Li Fraumeni syndrome" table on the next page for management guidelines.

Pathogenic or Likely Pathogenic Variants of Unknown Origin in the TP53 Gene The patient's test report includes a COMMENT about the possibility of somatic origin				
	<i>TP53</i> variants found in blood, saliva, or buccal samples may be present from birth (germline) or acquired later in life (somatic).			
Clinical correlation	 Your patient's test report will indicate if the pathogenic or likely pathogenic TP53 variant is of uncertain origin 			
	 It is not always possible to distinguish definitively between germline and acquired (somatic) variants. Clinical presentation may help guide management of these patients. 			
	Aberrant clonal expansion (ACE) due to clonal hematopoiesis (CHiP)			
Reasons for somatic TP53 variants identified	 Common in healthy older age populations (over 65 years) 			
in blood or saliva	Chemotherapy treatment			
	Radiation treatment			
	Management of individuals with pathogenic or likely pathogenic <i>TP53</i> variants will differ markedly			
	depending on if the TP53 variant is germline or acquired (somatic).			
	 Testing of family members (such as siblings, parents, and/or children) can help distinguish between germline and acquired (somatic) variants, although it is not always possible to do so.^{1,2} 			
Management and Next Steps	 Acquired (somatic) TP53 variants: these individuals do not have Li Fraumeni syndrome (LFS) and are not at increased risk for LFS cancers. Management is based on personal and family history. 			
	 These individuals may be at risk for heart disease or blood cancers.¹ 			
	Careful examination of the patient's complete blood count (CBC) and peripheral blood smear may be warranted in all individuals with identified <i>TP53</i> variants and testing of non-hematopoietic tissue(s) may help confirm true mosaic involvement across different germ layers. ^{1,2}			

1. Weitzel J, et al. Genet Med 2018;20:809 816.

2. Chao E, et al. Genet Med 2021 Jul;23(7):1179 1184.

Li Fraumeni Syndrome The patient's test report states that the result is consistent with a diagnosis of Li Fraumeni syndrome (LFS), which is caused by germline pathogenic or likely pathogenic variants in the *TP53* gene

SCREENING/SURGICAL CONSIDERATIONS ¹ AGE TO START FREQUENCY				
Female Breast Can				
Breast Awareness				
	amiliar with their breasts t changes to their healthcare	18 years old	Periodic and consistent	
Clinical Breast Exa	m	20 years old (or at the age of earliest diagnosed breast cancer in the family), whichever comes first	Every 6-12 months	
Breast Screening	Breast MRI with and without contrast	20-29 years old (or at the age of earliest diagnosed breast cancer in the family), whichever comes first, including women treated for breast cancer and who have not had bilateral mastectomy	Every 12 months, Individualized after 75 years old	
	Breast MRI with and without contrast and mammogram	30-75 years old, including women treated for breast cancer and who have not had bilateral mastectomy		
Discuss option of ri	sk-reducing mastectomy	Individualized	N/A	
Brain Tumors				
Brain MRI as part o Other Cancers), or	f whole body MRI (see below, a separate exam	Individualized	Every 12 months	
Neurologic exam**		Individualized	Every 6-12 months	
Colorectal and Inte	stinal Cancer			
Colonoscopy and u	pper endoscopy	25 years old, or 5 years before earliest known colon or gastric cancer in the family (whichever comes first)	Every 2-5 years	
or abdominal thera	ave received whole body peutic radiation treatment, ning is recommended	5 years after treatment of disease	Every 2-5 years	
Melanoma				
Dermatologic exam	1	18 years old	Every 12 months	
Pancreatic Cancer				
For individuals with exocrine pancreatic cancer in ≥1 first-or second-degree relative on the same side of the family as the identified pathogenic/likely pathogenic germline variant, consider pancreatic cancer screening using contrast-enhanced MRI/ MRCP and/or EUS.^		50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family)	Every 12 months (with consideration of shorter intervals if worrisome abnormalities seen on screening)	
Prostate Cancer				
Prostate-specific a	ntigen (PSA) testing	40 years old	Individualized	
Pediatric Surveillan	ice			
Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors		Infancy	Every 6-12 months	
Whole body MRI. Brain MRI may be performed as part of the whole body MRI or as a separate exam.		Infancy	Every 12 months	
Ultrasound for adre	enocortical carcinoma	Infancy	Every 3-4 months	

Other Aspects of Managing LFS				
The screening and management of LFS is complex and LFS is rare; it is preferred that individuals with LFS be followed at centers with expertise in the management of this syndrome.	N/A	N/A		
Address limitations of screening for many cancers associated with Li-Fraumeni syndrome (LFS). Screening should be considered for cancer survivors with LFS and a good prognosis from their prior tumor(s).	N/A	N/A		
Screening recommendations should take into account personal and family history of cancer. Provide additional surveillance based on family history of cancer.	5-10 years before the earliest diagnosis	Individualized		
Therapeutic radiation treatment for cancer should be avoided when possible unless locoregional risk reduction or overall survival from radiation treatment is greater than the risk of downstream secondary malignancies; diagnostic radiation should be minimized to the extent feasible without sacrificing accuracy.	N/A	N/A		
Provide education regarding signs and symptoms of cancer.	N/A	N/A		
Address psychosocial and quality-of-life aspects of management	N/A	N/A		

** This may be done as part of the comprehensive physical exam

A For individuals considering pancreatic cancer screening, the Guidelines recommends that screening be performed in experienced high-volume centers. The Guidelines recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of benign or intermediate pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. The Guidelines recommends that screening be considered using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening for individuals found to have worrisome abnormalities on screening. The Guidelines emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention.

 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. v2.2025.

 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 7, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. v3.2024.© National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed October 31, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.